文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

脂质纳米粒中紫杉醇和大麻二酚的共递送增强对黑色素瘤细胞的细胞毒性。

Codelivery of Paclitaxel and Cannabidiol in Lipid Nanoparticles Enhances Cytotoxicity against Melanoma Cells.

作者信息

de Carvalho Fabíola V, Geronimo Gabriela, de Moura Ludmilla D, Mendonça Talita C, Breitkreitz Márcia Cristina, de Paula Eneida, Rodrigues da Silva Gustavo H

机构信息

Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), 13083-862 Campinas, São Paulo, Brazil.

Department of Analytical Chemistry, Institute of Chemistry, University of Campinas (UNICAMP), 13083-970 Campinas, São Paulo, Brazil.

出版信息

ACS Omega. 2025 May 22;10(21):21568-21580. doi: 10.1021/acsomega.5c00689. eCollection 2025 Jun 3.


DOI:10.1021/acsomega.5c00689
PMID:40488002
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12138705/
Abstract

Although chemotherapy regimens are well-established in clinical practice, chemoresistance and adverse side effects pose significant obstacles in cancer treatment. Paclitaxel (PTX), a widely used chemotherapeutic agent, faces formulation challenges due to its poor solubility and permeability. Research suggests that the phytochemical Cannabidiol (CBD) holds potential not only in targeting cancer cells but also in alleviating pain and nausea, thereby improving the quality of life for cancer patients. However, CBD's clinical application is also limited by its poor solubility, low bioavailability, and susceptibility to oxidation. Nanostructured lipid carriers (NLCs) represent a promising drug delivery system for hydrophobic compounds like PTX and CBD and allow their coencapsulation. Nonetheless, achieving a stable formulation requires the identification of suitable preparation methods and excipients. The aim of this study was to develop and optimize an NLC formulation for the coencapsulation of PTX and CBD. Using factorial design, an optimized formulation was obtained with homogeneous particle sizes (200 nm), negative ZPs (-16.1 mV), a particle concentration of 10 particles/mL, spherical morphology (TEM images), and a lipid core with low crystallinity (confirmed by XRD). To evaluate the therapeutic potential of the drug combination, cell viability assays were conducted on murine melanoma cells (B16-F10) at different exposure times (24 and 48 h). The NLC-CBD-PTX formulation significantly reduced cell viability in a time- and concentration-dependent manner, demonstrating at least 75% greater activity at 24 h compared to each drug individually, whether free (PTX, CBD) or encapsulated (NLC-PTX, NLC-CBD). This indicates a synergistic effect between CBD and PTX when coencapsulated, particularly at higher concentrations and shorter exposure times. In conclusion, an innovative pharmaceutical formulation coencapsulating PTX and CBD was validated, showing potential to enhance antitumor efficacy, overcome chemoresistance, reduce side effects, and broaden therapeutic applications. The resulting NLCs exhibited favorable physicochemical properties, supporting their suitability for various routes of administration.

摘要

尽管化疗方案在临床实践中已得到充分确立,但化疗耐药性和不良副作用在癌症治疗中构成了重大障碍。紫杉醇(PTX)是一种广泛使用的化疗药物,由于其溶解性和渗透性差而面临制剂挑战。研究表明,植物化学物质大麻二酚(CBD)不仅在靶向癌细胞方面具有潜力,而且在减轻疼痛和恶心方面也有潜力,从而提高癌症患者的生活质量。然而,CBD的临床应用也受到其溶解性差、生物利用度低和易氧化的限制。纳米结构脂质载体(NLCs)是一种有前途的药物递送系统,可用于递送PTX和CBD等疏水性化合物,并允许它们共包封。尽管如此,要获得稳定的制剂需要确定合适的制备方法和辅料。本研究的目的是开发和优化一种用于共包封PTX和CBD的NLC制剂。采用析因设计,获得了一种优化制剂,其粒径均匀(200 nm)、Zeta电位为负(-16.1 mV)、颗粒浓度为10个颗粒/mL、呈球形形态(透射电镜图像)且脂质核心结晶度低(X射线衍射证实)。为了评估药物组合的治疗潜力,在不同暴露时间(24小时和48小时)对小鼠黑色素瘤细胞(B16-F10)进行了细胞活力测定。NLC-CBD-PTX制剂以时间和浓度依赖性方式显著降低细胞活力,与单独使用每种药物(无论是游离的(PTX、CBD)还是包封的(NLC-PTX、NLC-CBD))相比,在24小时时显示出至少75%更高的活性。这表明CBD和PTX共包封时具有协同作用,特别是在较高浓度和较短暴露时间下。总之,一种共包封PTX和CBD的创新药物制剂得到了验证,显示出增强抗肿瘤疗效、克服化疗耐药性、减少副作用和拓宽治疗应用的潜力。所得的NLCs表现出良好的物理化学性质,支持它们适用于各种给药途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1fe/12138705/cb21649b2ac0/ao5c00689_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1fe/12138705/98fa5a7cb066/ao5c00689_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1fe/12138705/5ae011b29393/ao5c00689_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1fe/12138705/af7230f3a1eb/ao5c00689_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1fe/12138705/6256cbd89d74/ao5c00689_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1fe/12138705/52f057903308/ao5c00689_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1fe/12138705/cb21649b2ac0/ao5c00689_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1fe/12138705/98fa5a7cb066/ao5c00689_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1fe/12138705/5ae011b29393/ao5c00689_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1fe/12138705/af7230f3a1eb/ao5c00689_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1fe/12138705/6256cbd89d74/ao5c00689_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1fe/12138705/52f057903308/ao5c00689_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1fe/12138705/cb21649b2ac0/ao5c00689_0006.jpg

相似文献

[1]
Codelivery of Paclitaxel and Cannabidiol in Lipid Nanoparticles Enhances Cytotoxicity against Melanoma Cells.

ACS Omega. 2025-5-22

[2]
Enhancement of cannabidiol oral bioavailability through the development of nanostructured lipid carriers: In vitro and in vivo evaluation studies.

Drug Deliv Transl Res. 2024-12-30

[3]
Targeted Nanostructured Lipid Carriers for Delivery of Paclitaxel to Cancer Cells: Preparation, Characterization, and Cell Toxicity.

Curr Drug Deliv. 2017

[4]
Development of α-Tocopherol Succinate-Based Nanostructured Lipid Carriers for Delivery of Paclitaxel.

Pharmaceutics. 2022-5-11

[5]
Lipoprotein-Inspired Nanocarrier Composed of Folic Acid-Modified Protein and Lipids: Preparation and Evaluation of Tumor-Targeting Effect.

Int J Nanomedicine. 2020-5-14

[6]
Enhancing ovarian cancer conventional chemotherapy through the combination with cannabidiol loaded microparticles.

Eur J Pharm Biopharm. 2020-9

[7]
Paclitaxel-loaded Nanolipidic Carriers with Improved Oral Bioavailability and Anticancer Activity against Human Liver Carcinoma.

AAPS PharmSciTech. 2019-1-23

[8]
CBD loaded microparticles as a potential formulation to improve paclitaxel and doxorubicin-based chemotherapy in breast cancer.

Int J Pharm. 2019-12-4

[9]
Development and optimization of transferrin-conjugated nanostructured lipid carriers for brain delivery of paclitaxel using Box-Behnken design.

Pharm Dev Technol. 2017-5

[10]
Mucoadhesive nanostructured lipid carriers as a cannabidiol nasal delivery system for the treatment of neuropathic pain.

Eur J Pharm Sci. 2021-4-1

本文引用的文献

[1]
Enhancement of cannabidiol oral bioavailability through the development of nanostructured lipid carriers: In vitro and in vivo evaluation studies.

Drug Deliv Transl Res. 2024-12-30

[2]
Development and Evaluation of Docetaxel-Loaded Nanostructured Lipid Carriers for Skin Cancer Therapy.

Pharmaceutics. 2024-7-19

[3]
Melanoma and cannabinoids: A possible chance for cancer treatment.

Exp Dermatol. 2024-7

[4]
Advanced multifunctional nano-lipid carrier loaded gel for targeted delivery of 5-flurouracil and cannabidiol against non-melanoma skin cancer.

Environ Res. 2023-9-15

[5]
The current role of cannabis and cannabinoids in health: A comprehensive review of their therapeutic potential.

Life Sci. 2023-9-15

[6]
Cannabidiol-Loaded Nanostructured Lipid Carriers (NLCs) for Dermal Delivery: Enhancement of Photostability, Cell Viability, and Anti-Inflammatory Activity.

Pharmaceutics. 2023-2-6

[7]
An update of nano-based drug delivery systems for cannabinoids: Biopharmaceutical aspects & therapeutic applications.

Int J Pharm. 2023-3-25

[8]
Nanodelivery systems for cutaneous melanoma treatment.

Eur J Pharm Biopharm. 2023-3

[9]
Docetaxel Loaded in Copaiba Oil-Nanostructured Lipid Carriers as a Promising DDS for Breast Cancer Treatment.

Molecules. 2022-12-13

[10]
Pluronic® triblock copolymer-based nanoformulations for cancer therapy: A 10-year overview.

J Control Release. 2023-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索